Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15. SPC-15 is an intranasal 5-HT4 receptor agonist designed to address post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders.
This Canadian allowance represents a significant expansion of Silo's intellectual property portfolio. The company holds an exclusive license to the Canadian patent application through a broader agreement with Columbia University, which grants Silo the rights to further develop, manufacture, and commercialize SPC-15 globally. The Canadian patent is part of a larger international strategy, as corresponding intellectual property has already been granted or is advancing in multiple markets. Notably, a European patent covering the same core invention was recently granted, reinforcing the global protection for this promising therapeutic candidate.
The development of SPC-15 is particularly noteworthy due to its potential to address the substantial unmet medical need in PTSD and related conditions. According to the U.S. Department of Veterans Affairs, PTSD affects millions of adults each year, and current treatment options are often limited by efficacy and tolerability issues. SPC-15, with its novel mechanism of action, may offer a new avenue for patients who do not respond adequately to existing therapies.
Silo Pharma intends to pursue the FDA's streamlined 505(b)(2) regulatory pathway for SPC-15. This approach allows the company to rely on existing published data for certain components of the application, potentially shortening clinical timelines and reducing development costs compared to traditional new drug applications. This strategic move could accelerate the time to market for SPC-15, bringing a much-needed treatment option to patients sooner.
The company's portfolio extends beyond SPC-15, including SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories, underscoring its commitment to scientific innovation. The company also operates a wholly owned managed AI agent platform subsidiary, reflecting its forward-thinking approach to drug development and corporate operations.
This Canadian patent allowance is a critical milestone for Silo Pharma as it strengthens the company's competitive position and validates the novelty of its lead asset. With corresponding patents secured in Europe and now Canada, Silo is building a robust global IP estate that could be attractive to potential partners or investors. The streamlined regulatory pathway for SPC-15 further enhances its commercial prospects, making this an important development for the biopharmaceutical industry and for patients suffering from stress-induced psychiatric disorders.
